Yahoo · Sep 5, 2026
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)
Owning these dividend stocks could be a simple way to make money over the long term.
AB
NYSE · ABBV
AbbVie Inc.
Healthcare · Drug Manufacturers - General
$256.46
Down-$3.87 (-1.49%)
Updated Sep 8, 2026, 6:56 AM
SID Score
7.3/10
Composite research score
Smart Money
53/100
Neutral
- Market cap
- 410.09B
- P/E ratio
- 97.75
- Dividend yield
- 3.23%
- 52-week range
- $190.75 – $267.47
- Volume
- 4.73M
- Avg. volume
- 6.4M
Price performance
ABBV price history
1M range · 20 trading sessions · Daily adjusted prices
ABBV closed at $256.46 after 20 trading sessions, up 3.42% for the selected period.
- Last close
- $256.46
- Period change
- +3.42%
- Period low
- $247.97
- Period high
- $265.97
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $257.96 | $258.91 | $255.58 | $256.46 | 4.73M |
| Sep 3, 2026 | $264.00 | $264.25 | $257.14 | $260.21 | 2.88M |
| Sep 2, 2026 | $262.70 | $262.97 | $257.70 | $261.72 | 4.23M |
| Sep 1, 2026 | $260.99 | $262.265 | $257.79 | $259.99 | 3.87M |
| Aug 31, 2026 | $254.17 | $258.24 | $252.33 | $256.42 | 4.32M |
| Aug 28, 2026 | $258.67 | $259.00 | $255.0797 | $255.48 | 3.22M |
| Aug 27, 2026 | $260.81 | $262.4977 | $257.25 | $258.15 | 4.76M |
| Aug 26, 2026 | $264.60 | $265.00 | $260.31 | $262.90 | 3.31M |
| Aug 25, 2026 | $264.50 | $266.905 | $263.025 | $265.79 | 3.67M |
| Aug 24, 2026 | $263.99 | $266.0395 | $262.07 | $264.52 | 3.88M |
| Aug 21, 2026 | $260.70 | $266.84 | $260.101 | $264.96 | 5.16M |
| Aug 20, 2026 | $265.69 | $265.93 | $260.4812 | $261.83 | 5.23M |
| Aug 19, 2026 | $261.51 | $266.965 | $259.55 | $265.97 | 5.54M |
| Aug 18, 2026 | $253.93 | $259.18 | $252.41 | $258.92 | 5.01M |
| Aug 17, 2026 | $249.49 | $251.49 | $248.31 | $250.33 | 4.65M |
| Aug 14, 2026 | $250.60 | $250.61 | $247.68 | $249.46 | 4.2M |
| Aug 13, 2026 | $252.94 | $255.295 | $249.35 | $250.82 | 4.37M |
| Aug 12, 2026 | $245.98 | $250.09 | $245.52 | $248.76 | 3.78M |
| Aug 11, 2026 | $248.14 | $250.765 | $247.18 | $250.09 | 4.49M |
| Aug 10, 2026 | $245.65 | $248.01 | $244.03 | $247.97 | 4.21M |
Latest ABBV news
The latest Smart Investors Daily articles mentioning ABBV.
Stock researchCompany · Overview
ABBV research
Overview
Company profile and research snapshot.
Company profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $258.83
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Piper Sandler | Overweight | — |
| Aug 17, 2026 | Wells Fargo | Overweight | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Aug 11, 2026 | BNP Paribas | Neutral | — |
| Aug 10, 2026 | Evercore ISI Group | Outperform | — |
News briefing
Generated Sep 7, 2026, 9:00 PM
Why Is ABBV Down Today?
AbbVie shares declined 1.49% today, closing down $3.87, amid a broader market environment where dividend stocks face rotation pressures. While the company continues to be recognized for its strong dividend credentials, including potential inclusion in dividend-focused portfolios, today's pullback suggests profit-taking or sector-wide headwinds affecting large-cap pharmaceutical and healthcare dividend payers.
Bottom line: AbbVie's 1.49% decline appears driven by sector rotation rather than fundamental concerns, as the company remains a recognized dividend powerhouse. For income-focused investors, today's pullback may represent a tactical buying opportunity, though monitor pipeline developments and broader pharma sector dynamics for potential headwinds.
Yahoo · Sep 4, 2026
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...
Yahoo · Sep 4, 2026
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Yahoo · Sep 4, 2026
Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AI research layers
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. Stock Performance
AbbVie Inc. shares closed at $256.34, reflecting a single-session decline of 1.32% per SID market data. Despite the daily pullback, the stock has demonstrated consistent upward momentum across multiple timeframes, gaining 5.16% over the past month, 12.86% over three months, and 14.94% over the trailing twelve months. The current price sits above both key moving averages, trading at a 0.73% premium to the 50-day moving average of $254.48 and a substantial 12.45% premium to the 200-day moving average of $227.96, according to SID market data. The 14-day relative strength index reads 56.6, indicating neutral momentum without overbought or oversold conditions. AbbVie maintains a market capitalization of approximately $410.1 billion with average daily trading volume of 6.4 million shares. The stock's beta of 0.334 reflects significantly lower volatility relative to the broader market, consistent with its defensive healthcare sector positioning.
AbbVie Inc. Valuation Analysis
AbbVie Inc. currently trades at a price-to-earnings ratio of 97.75, a notably elevated multiple that reflects the earnings impact of significant amortization charges tied to the company's acquisition-driven business model, per SID market data. The PEG ratio stands at 1.25, suggesting the stock is trading modestly above fair value when factoring in projected earnings growth. The company's price-to-book ratio registers at a negative 126.33, a direct consequence of accumulated goodwill impairments and intangible asset amortization that have resulted in negative book value on the balance sheet, according to SEC filings. AbbVie offers a dividend yield of 2.87%, positioning it as a meaningful income-generating holding within the healthcare sector. The negative book value is a structural feature common among pharmaceutical companies that have pursued large-scale acquisitions, including AbbVie's $63 billion Allergan purchase, rather than an indication of financial distress. Investors typically evaluate AbbVie on cash-flow-based metrics rather than book value multiples.
Smart Money Activity for ABBV
AbbVie Inc. registers a composite smart money score of 54 out of 100 with a neutral overall signal, according to SID market data. The institutional component scores a perfect 25 out of 25, reflecting exceptionally strong conviction among large asset managers and fund complexes. Insider activity scores 18 out of 25, supported by two insider purchases and zero insider sales recorded over the past 90 days per SEC Form 4 filings, a directionally positive indicator suggesting corporate officers and directors view current price levels as attractive. Dark pool activity scores a below-average 9.8 out of 25, indicating relatively subdued off-exchange block trading interest in recent periods. Congressional trading activity is minimal at 0.8 out of 25, showing negligible positioning by members of Congress, per 13F institutional filings. The divergence between strong institutional conviction and moderate dark pool activity suggests that large holders are maintaining existing positions rather than actively accumulating new shares at current valuation levels. The insider buying pattern warrants monitoring for continuation.
AbbVie Inc. Earnings Outlook
AbbVie Inc. has delivered a mixed earnings trajectory across recent quarters, according to company earnings reports. In the most recent reported quarter, the company posted earnings per share of $2.65 against a consensus estimate of $2.66, resulting in a marginal miss of $0.01. The prior quarter showed a positive surprise of $0.05, with actual EPS of $2.71 exceeding the $2.66 estimate. However, the earliest available forward quarter reflects a more significant miss, with actual EPS of $3.65 falling $0.12 below the $3.77 consensus estimate per analyst estimates. The upcoming quarter carries a consensus EPS estimate of $3.01, with results not yet reported. AbbVie's earnings pattern shows sequential growth from $2.66 to $2.71 to $2.65 in reported actuals, reflecting relative stability. The company faces ongoing revenue transition headwinds as Humira biosimilar competition intensifies, while newer immunology assets Skyrizi and Rinvoq continue scaling toward offsetting lost exclusivity revenue.
Wall Street Analyst Ratings for ABBV
Wall Street coverage of AbbVie Inc. reflects a predominantly constructive outlook, with recent analyst actions skewing toward positive or neutral positioning, per Wall Street analyst reports. Piper Sandler reiterated its Overweight rating on August 20, 2026, while Wells Fargo maintained its Overweight rating on August 17, 2026, signaling sustained confidence from two major sell-side firms. Notably, Wolfe Research upgraded ABBV to Outperform from Peer Perform on August 13, 2026, representing the most directionally significant rating change in the recent period according to SID consensus data. Evercore ISI Group maintained its Outperform rating on August 10, 2026, further reinforcing bullish sentiment. BNP Paribas stands as the lone neutral voice, reiterating its Neutral rating on August 11, 2026. Across these five most recent actions, four firms carry bullish-equivalent ratings while one remains neutral, with no underweight or sell ratings present. The Wolfe Research upgrade suggests broadening analyst confidence in AbbVie's portfolio transition beyond Humira dependency.
